Table 3.
Effect of atazanavir/ritonavir on the plasma pharmacokinetic parameters of buprenorphine and buprenorphine metabolites
| Pharmacokinetic Parameter | Pre- ATV/r | Post- ATV/r | p value |
|---|---|---|---|
| Buprenorphine | |||
| AUC0-24 (ng*h/ml) | 46.2 (4.3) | 77.0 (6.9) | <0.001 |
| CI/F (L/h) | 390 (55) | 226 (23) | 0.002 |
| Cmax (ng/ml) | 5.79 (0.59) | 7.95 (1.06) | 0.002 |
| Tmax (h) | 1.00 (0.5-2) | 1.25 (0.5-2) | n.s. |
| Cmin (ng/ml) | 1.09 (0.11) | 1.84 (0.22) | 0.002 |
| Norbuprenorphine | |||
| AUC0-24 (ng*h/ml) | 65.8 (6.3) | 135 (21.6) | 0.006 |
| CI/F (L/h) | 267 (28) | 155 (29) | <0.001 |
| Cmax (ng/ml) | 4.60 (0.52) | 7.42 (0.88) | 0.01 |
| Tmax (h) | 1.5 (0.5-4) | 2.0 (0.5-8) | n.s. |
| Cmin (ng/ml) | 1.97 (0.23) | 3.95 (0.66) | 0.01 |
| Buprenorphine-3-Glucuronide | |||
| AUC0-24 (ng*h/ml) | 28.1 (5.9) | 132 (25.5) | 0.001 |
| CI/F (L/h) | 1242 (425) | 184 (41) | 0.025 |
| Cmax (ng/ml) | 4.97 (1.28) | 25.6 (6.22) | 0.007 |
| Tmax (h) | 1.0 (0.5-1.5) | 1.75 (0.5-8) | 0.05 |
| Cmin (ng/ml) | 0.36 (0.08) | 1.28 (0.33) | 0.014 |
| Norbuprenorphine-3-Glucuronide | |||
| AUC0-24 (ng*h/ml) | 312 (54) | 432 (66) | 0.037 |
| CI/F (L/h) | 72 (15) | 56 (16) | 0.14 |
| Cmax (ng/ml) | 23.6 (4.6) | 31.5 (6.8) | 0.19 |
| Tmax (h) | 1.75 (1-12) | 5.0 (1.5-8) | n.s. |
| Cmin (ng/ml) | 7.62 (1.20) | 12.0 (1.92) | 0.018 |
Note: Values are the mean (standard error of the mean) for 10 subjects who participated in both sessions, except that the discontinuous variable, Tmax, is given as median (range). Student's paired t-test was used to determine p-values for all parameters except Tmax, where the Wilcoxon test was used.